Brief Introduction

Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes in high-purity, low polydispersity polyethylene glycol (PEG) material synthesis and PEGylation related technique services. In 2007, JenKem Technology opened its international business office in Dallas, TX for overseas business development, serving all customers located outside mainland China. In the same year, JenKem Technology Tianjin was founded in Tianjin Economic-Technological Development Area (TEDA) as the main manufacture plant of the company. The Newest facility was founded in 2016 in Panjin, Liaoning as the production site for PEG raw material manufacture.

JenKem's specific strengths are supported by the know-hows accumulated during the 20 years of the experience in the performance of all polymerizations and derivatizations.JenKem Technology is capable to supply PEG derivatives worldwide, from R&D through GMP commercial quantities, for preclinical, clinical trials, and commercial products for pharma, biotech, medical devices, and diagnostics, with thedevelopment and manufacture of a wide range of more than 600 different derivatives in catalogue with high purity and low polydispersity, currently in 1 gram to 40 kg or greater sized batches, under ISO 9001 and ISO 13485 certified Quality Management Systems, following ICH Q7A guidelines. JenKem Technology has supported 4 of all the 6 PEGylation drugs on the China market as well as several medical devices from Cardinal Health, Medtronic and Boston Scientific on the international market. JenKem also supports tens of projects on clinical stage and has more than 600 customers of universities or research institutions.

The R&D team accounts for more than 20% of all the JenKem staff. Most of our R&D members graduate from the School of Pharmacy or Material Science of well-known universities and are experienced in the research and application of PEG materials. JenKem Technology respects the intellectual property of others and has the capability to file for patents worldwide to protect customers' interests. As of July 2020, JenKem Technology has 67 patent approvals (35 in China, 20 in US, 8 in Europe, 3 in Japan, 1 in Australia), 48 pending patent applications (22 in China, 16 in US, 5 in Europe, 1 in India, 1 in Brazil, 1 in Korea, 2 PCT), and many other innovative technologies under development.JenKem Technology has filed DMFs for several of its PEG products, and will file other DMFs with the FDA at customers' request.

Company Overview

Full name JenKem Technology Co., Ltd
Abbreviations JenKem Technology
Code 688356
Founded Oct 9, 2001
Listing Aug 26, 2020
Domicile Haidian District, Beijing
STAR Theme Biomedicine
CSRC Sector Fine Chemical
Has weighted voting rights structure? No



  2020 2019 2018
Earnings Per Share 1.71 1.37 0.81
R&D expenditure as a % of operating revenue 14.09% 15.41% 12.98%
Operating Revenue 101,052,033.38 70,746,860.21 42,593,978.92
Net Income 85,678,928.62 61,543,677.14 36,269,714.23

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 101.5 70.75 42.59
Operating Costs 26.19 21.08 19.03
Operating Income 186.62 134.32 101.27
Pretax Income 101.03 70.60 42.55
Income Tax 15.35 9.06 6.28
Net Income 85.68 61.54 36.27

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Current Assets-Total 785.06 164.61 121.31
Non-current Assets-Total 115.55 103.84 95.05
Total Assets 900.61 268.45 216.35
Current Liabilities-Total 41.31 44.78 44.03
Non-current Liabilities-Total 3.06 3.32 3.63
Total Liabilities 44.37 48.10 47.66
Stockholder's Equity
Share Capital 60.00 45.00 45.00
Retained Profits 187.85 105.56 54.20
Total Owners' Equity 856.24 220.35 168.70

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating 78.22 51.00 33.68
Net Cash Flows-Investing -18.31 1.25 -17.39
Net Cash Flows-Financing 552.66 -12.99 -7.51

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
Xuan Zhao 14.87 24.78
Kaiting Wu 9.15 15.24
Huimin Liu 8.92 14.87
Feihong Zhu 2.98 4.96
Beijing JianYe TengFei Company Consultation Management Center 2.25 3.75
Shanghai ManLu Investment ManagementPartnership 2.22 3.70
Shuimu Development Limited 1.88 3.14
Beijing Tianyi Xihui Investment Management Partnership 1.88 3.14
Guojun Venture Capital Zhengjun No.3 Equity Investment Partnership 0.85 1.42
Universal Medical Service Flexibly Allocates Hybrid Securities Investment Funds 0.77 1.28
As of 2020-12-31

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.